Author Archives: Charles Moore

Medication-Blocking Mucus Barrier in Lungs Breached Using Nanoparticles

The first nanotechnology-enabled gene delivery system capable of efficiently penetrating the hard-to-breach mucus barrier shielding human airway and lung tissue may have been discovered with potential to one day develop an inhaled vehicle for delivery of targeted therapeutic genes that may be delivered directly to the lungs at levels sufficient…

FDA Approves ORKAMBI, New Cystic Fibrosis Combination Drug

The U.S. Food and Drug Administration on Thursday, July 2 announced that it has approved the first cystic fibrosis treatment that targets the cause of the disease. Orkambi is an oral ivacaftor/lumacaftor combination medication for treatment of CF that targets the underlying cause of the disease in people who have…

Cystic Fibrosis Foundation Awards $2.8 Million To Novoteris, LLC For Development of Inhaled Nitric Oxide CF Therapy

Garden Grove, California based Novoteris, LLC has received $2.8 million in funding from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) to develop an inhaled nitric oxide antimicrobial therapy for people with cystic fibrosis (CF) who have airway bacterial colonization. CFFT is the nonprofit drug discovery and development affiliate of the Cystic…

Cystic Fibrosis Therapy Developer Announces Initial Public Offering

Boulder, Colorado based Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), recently announced its initial public offering (IPO) which included 5.5 million shares of common stock priced at $14.00 per share before underwriting discounts and commissions. Nivalis additionally granted underwriters a 30-day option…

Celtaxsys Raises $45M For Novel Anti-inflammatory CF Drug Phase 2 Research

The lead drug candidate under development by Celtaxsys — an Atlanta, Georgia based clinical-stage development company focused on novel therapeutics for treating inflammatory disease through regulation of immune cell migration and activation — is CTX-4430, described as a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor that shows promise as…


Featured Column

Don’t Overlook Emotional Wellness When Dealing With Chronic Illness

A banner for Lara's column, depicting a car on a road trip winding through a forest.
Living with a chronic illness can affect emotional wellness, writes columnist Lara Govendo, who offers up some ideas for managing both.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.